<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36416308</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1208</StartPage><EndPage>1222</EndPage><MedlinePgn>1208-1222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddac287</ELocationID><Abstract><AbstractText>Mitochondrial involvement in neurodegenerative diseases is widespread and multifactorial. Targeting mitochondrial pathology is therefore of interest. The recent development of bioactive molecules that modulate mitochondrial dynamics (fusion, fission and motility) offers a new therapeutic approach for neurodegenerative diseases with either indirect or direct mitochondrial involvement. Here, we asked: (1) Can enhanced mitochondrial fusion and motility improve secondary mitochondrial pathology in superoxide dismutase1 (SOD1) mutant amyotrophic lateral sclerosis (ALS)? And: (2) What is the impact of enhancing mitochondria fitness on in vivo manifestations of SOD1 mutant ALS? We observed that small molecule mitofusin activators corrected mitochondrial fragmentation, depolarization and dysmotility in genetically diverse ALS patient reprogrammed motor neurons and fibroblasts, and in motor neurons, sensory neurons and fibroblasts from SOD1 G93A mice. Continuous, but not intermittent, pharmacologic mitofusin activation delayed phenotype progression and lethality in SOD1 G93A mice, reducing neuron loss and improving neuromuscular connectivity. Mechanistically, mitofusin activation increased mitochondrial motility, fitness and residency within neuromuscular synapses; reduced mitochondrial reactive oxygen species production; and diminished apoptosis in SOD1 mutant neurons. These benefits were accompanied by improved mitochondrial respiratory coupling, despite characteristic SOD1 mutant ALS-associated downregulation of mitochondrial respiratory complexes. Targeting mitochondrial dysdynamism is a promising approach to alleviate pathology caused by secondary mitochondrial dysfunction in some neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Xiawei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-0343-7107</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis MO USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis MO USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Antonietta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis MO USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorn Ii</LastName><ForeName>Gerald W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis MO USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R42 NS113642</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 HL135736</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R42 NS115184</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>11062-77-4</RegistryNumber><NameOfSubstance UI="D013481">Superoxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013481" MajorTopicYN="N">Superoxides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>G.W.D. is an inventor on multiple patents owned by Washington University and other entities that cover the use of small molecule mitofusin activators to treat neurodegenerative diseases. G.W.D. is the founder of Mitochondria in Motion, Inc., a Saint Louis based biotech R&amp;D company that aims to enhance mitochondrial trafficking and fitness in neurodegenerative diseases. The other authors declare no competing interests. Studies with MiM111 and CPR1 were performed under terms of an MTA between Mitochondria in Motion, Inc. and Washington University in St. Louis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36416308</ArticleId><ArticleId IdType="pmc">PMC10026224</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddac287</ArticleId><ArticleId IdType="pii">6843060</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knott, A.B., Perkins, G., Schwarzenbacher, R. and Bossy-Wetzel, E. (2008) Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci., 9, 505&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711514</ArticleId><ArticleId IdType="pubmed">18568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Burte, F., Carelli, V., Chinnery, P.F. and Yu-Wai-Man, P. (2015) Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat. Rev. Neurol., 11, 11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">25486875</ArticleId></ArticleIdList></Reference><Reference><Citation>Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G.P., Bresolin, N. and Masliah, E. (2020) The role of mitochondria in neurodegenerative diseases, the lesson from Alzheimer's disease and Parkinson's disease. Mol. Neurobiol., 57, 2950&#x2013;2980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047992</ArticleId><ArticleId IdType="pubmed">32445085</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J.P., Deng, H.X. &#xa0;et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, 59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, H.X., Hentati, A., Tainer, J.A., Iqbal, Z., Cayabyab, A., Hung, W.Y., Getzoff, E.D., Hu, P., Herzfeldt, B., Roos, R.P. &#xa0;et al. (1993) Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science, 261, 1047&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong, J. and Xu, Z. (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci., 18, 3241&#x2013;3250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi, M., D'Aurelio, M., Gajewski, C.D., Martushova, K., Kiaei, M., Beal, M.F. and Manfredi, G. (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem., 277, 29626&#x2013;29633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos, K.J., Chapman, A.L., Tennant, M.E., Manser, C., Tudor, E.L., Lau, K.F., Brownlees, J., Ackerley, S., Shaw, P.J., McLoughlin, D.M. &#xa0;et al. (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet., 16, 2720&#x2013;2728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516806</ArticleId><ArticleId IdType="pubmed">17725983</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9;, J., Cortez, C., Gan, W.B. and Manfredi, G. (2014) Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet., 23, 1413&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafuri, F., Ronchi, D., Magri, F., Comi, G.P. and Corti, S. (2015) SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front. Cell. Neurosci., 9, 336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548205</ArticleId><ArticleId IdType="pubmed">26379505</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, E.F., Shaw, P.J. and De Vos, K.J. (2019) The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett., 710, 132933.</Citation><ArticleIdList><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma, D., Rognoni, F., van &#xa0;Duijn, W., Verspaget, H.W., Haasdijk, E.D. and Holstege, J.C. (2001) CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol., 102, 293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603803</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J., Lillo, C., Jonsson, P.A., Vande Velde, C., Ward, C.M., Miller, T.M., Subramaniam, J.R., Rothstein, J.D., Marklund, S., Andersen, P.M. &#xa0;et al. (2004) Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron, 43, 5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233913</ArticleId></ArticleIdList></Reference><Reference><Citation>Culik, R.M., Sekhar, A., Nagesh, J., Deol, H., Rumfeldt, J.A.O., Meiering, E.M. and Kay, L.E. (2018) Effects of maturation on the conformational free-energy landscape of SOD1. Proc. Natl. Acad. Sci. U. S. A., 115, E2546&#x2013;e2555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856554</ArticleId><ArticleId IdType="pubmed">29483249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligon, L.A., LaMonte, B.H., Wallace, K.E., Weber, N., Kalb, R.G. and Holzbaur, E.L. (2005) Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport, 16, 533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15812301</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, W., Pasinelli, P. and Trotti, D. (2014) Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 1842, 1295&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074562</ArticleId><ArticleId IdType="pubmed">24568860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S., Zhao, J., Quan, Z., Li, H. and Qing, H. (2022) Mitochondria and other organelles in neural development and their potential as therapeutic targets in neurodegenerative diseases. Front. Neurosci., 16, 853911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016280</ArticleId><ArticleId IdType="pubmed">35450015</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto, H.H. (2014) First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br. J. Pharmacol., 171, 2029&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976620</ArticleId><ArticleId IdType="pubmed">24117165</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, X., Qvit, N., Su, Y.C. and Mochly-Rosen, D. (2013) A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci., 126, 789&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619809</ArticleId><ArticleId IdType="pubmed">23239023</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N.Y., Szeto, H.H. and Beal, M.F. (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem., 98, 1141&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16895581</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi, A.U., Saw, N.L., Vogel, H., Cunnigham, A.D., Shamloo, M. and Mochly-Rosen, D. (2018) Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol. Med., 10, e8166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840540</ArticleId><ArticleId IdType="pubmed">29335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, D.C. (2020) Mitochondrial dynamics and its involvement in disease. Annu. Rev. Pathol., 15, 235&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">31585519</ArticleId></ArticleIdList></Reference><Reference><Citation>Santel, A. and Fuller, M.T. (2001) Control of mitochondrial morphology by a human mitofusin. J. Cell Sci., 114, 867&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn, G.W., 2nd (2019) Evolving concepts of mitochondrial dynamics. Annu. Rev. Physiol., 81, 1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30256725</ArticleId></ArticleIdList></Reference><Reference><Citation>Detmer, S.A. and Chan, D.C. (2007) Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. J. Cell Biol., 176, 405&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063976</ArticleId><ArticleId IdType="pubmed">17296794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang, X., Walton, E.K., Zablocka, B., Baloh, R.H., Shy, M.E., Dorn, G.W. and 2nd. (2022) Mitochondrial phenotypes in genetically diverse neurodegenerative diseases and their response to mitofusin activation. Cell, 11, 1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947610</ArticleId><ArticleId IdType="pubmed">35326504</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh, R.H., Schmidt, R.E., Pestronk, A. and Milbrandt, J. (2007) Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci., 27, 422&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672077</ArticleId><ArticleId IdType="pubmed">17215403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal, N., van &#xa0;Hameren, G., Juneja, M., Pellegrino, C., Louhivuori, L., Bartesaghi, L., Rochat, C., El Mansour, O., M&#xe9;dard, J.J., Croisier, M. &#xa0;et al. (2019) Altered interplay between endoplasmic reticulum and mitochondria in Charcot-Marie-Tooth type 2A neuropathy. Proc. Natl. Acad. Sci. U. S. A., 116, 2328&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369737</ArticleId><ArticleId IdType="pubmed">30659145</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco, A., Dang, X., Walton, E.K., Ho, J.N., Zablocka, B., Ly, C., Miller, T.M., Baloh, R.H., Shy, M.E., Yoo, A.S. &#xa0;et al. (2020) Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A. elife, 9, e61119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7655101</ArticleId><ArticleId IdType="pubmed">33074106</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavon, C.R., Shadel, G.S. and Manor, U. (2021) Impaired mitochondrial mobility in Charcot-Marie-Tooth disease. Front. Cell Dev. Biol., 9, 624823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7882694</ArticleId><ArticleId IdType="pubmed">33598463</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh, R.H. (2008) Mitochondrial dynamics and peripheral neuropathy. Neuroscientist, 14, 12&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911220</ArticleId></ArticleIdList></Reference><Reference><Citation>Misko, A., Jiang, S., Wegorzewska, I., Milbrandt, J. and Baloh, R.H. (2010) Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J. Neurosci., 30, 4232&#x2013;4240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852190</ArticleId><ArticleId IdType="pubmed">20335458</ArticleId></ArticleIdList></Reference><Reference><Citation>Naon, D. and Scorrano, L. (2014) At the right distance, ER-mitochondria juxtaposition in cell life and death. Biochim. Biophys. Acta, 1843, 2184&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24875902</ArticleId></ArticleIdList></Reference><Reference><Citation>Janikiewicz, J., Szyma&#x144;ski, J., Malinska, D., Patalas-Krawczyk, P., Michalska, B., Duszy&#x144;ski, J., Giorgi, C., Bonora, M., Dobrzyn, A. and Wieckowski, M.R. (2018) Mitochondria-associated membranes in aging and senescence, structure, function, and dynamics. Cell Death Dis., 9, 332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832430</ArticleId><ArticleId IdType="pubmed">29491385</ArticleId></ArticleIdList></Reference><Reference><Citation>Emery, J.M. and Ortiz, R.M. (2021) Mitofusin 2, A link between mitochondrial function and substrate metabolism? &#xa0;Mitochondrion, 61, 125&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">34536562</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X. &#xa0;et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264, 1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, L.J. (2007) Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev. Neurosci., 18, 115&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">17593875</ArticleId></ArticleIdList></Reference><Reference><Citation>Beresewicz, M., Boratynska-Jasinska, A., Charzewski, L., Kawalec, M., Kabzinska, D., Kochanski, A., Krzysko, K.A. and Zablocka, B. (2017) The effect of a novel c.820C&gt;T (Arg274Trp) mutation in the mitofusin 2 gene on fibroblast metabolism and clinical manifestation in a patient. PLoS One, 12, e0169999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5226824</ArticleId><ArticleId IdType="pubmed">28076385</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguer, C., Gambarotta, D., Mailloux, R.J., Moffat, C., Dent, R., McPherson, R. and Harper, M.E. (2011) Galactose enhances oxidative metabolism and reveals mitochondrial dysfunction in human primary muscle cells. PLoS One, 6, e28536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240634</ArticleId><ArticleId IdType="pubmed">22194845</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn, G.W., 2nd and Dang, X. (2022) Predicting mitochondrial dynamic behavior in genetically defined neurodegenerative diseases. Cell, 11, 1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947719</ArticleId><ArticleId IdType="pubmed">35326500</ArticleId></ArticleIdList></Reference><Reference><Citation>van der &#xa0;Bliek, A.M., Shen, Q. and Kawajiri, S. (2013) Mechanisms of mitochondrial fission and fusion. Cold Spring Harb. Perspect. Biol., 5, a011072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660830</ArticleId><ArticleId IdType="pubmed">23732471</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley, L.C., Christensen, M.E. and Waterhouse, N.J. (2016) Measuring mitochondrial transmembrane potential by TMRE staining. Cold Spring Harb Protoc, 2016, pdb.prot087361.</Citation><ArticleIdList><ArticleId IdType="pubmed">27934682</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang, X., Zhang, L., Franco, A., Li, J., Rocha, A.G., Devanathan, S., Dolle, R.E., Bernstein, P.R. and Dorn, G.W., 2nd (2020) Discovery of 6-phenylhexanamide derivatives as potent stereoselective mitofusin activators for the treatment of mitochondrial diseases. J. Med. Chem., 63, 7033&#x2013;7051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731667</ArticleId><ArticleId IdType="pubmed">32506913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha, A.G., Franco, A., Krezel, A.M., Rumsey, J.M., Alberti, J.M., Knight, W.C., Biris, N., Zacharioudakis, E., Janetka, J.W., Baloh, R.H. &#xa0;et al. (2018) MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science, 360, 336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6109362</ArticleId><ArticleId IdType="pubmed">29674596</ArticleId></ArticleIdList></Reference><Reference><Citation>Abernathy, D.G., Kim, W.K., McCoy, M.J., Lake, A.M., Ouwenga, R., Lee, S.W., Xing, X., Li, D., Lee, H.J., Heuckeroth, R.O. &#xa0;et al. (2017) MicroRNAs induce a permissive chromatin environment that enables neuronal subtype-specific reprogramming of adult human fibroblasts. Cell Stem Cell, 21, 332&#x2013;348.e339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679239</ArticleId><ArticleId IdType="pubmed">28886366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang, X., Williams, S.B., Devanathan, S., Franco, A., Fu, L., Bernstein, P.R., Walters, D., Dorn, G.W. and 2nd. (2021) Pharmacophore-based design of phenyl-[hydroxycyclohexyl] cycloalkyl-carboxamide mitofusin activators with improved neuronal activity. J. Med. Chem., 64, 12506&#x2013;12524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632069</ArticleId><ArticleId IdType="pubmed">34415150</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet, S.J., Furrer, S.A., Damian, V.M., Baughan, T.D., La Spada, A.R. and Garden, G.A. (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp., 39, 1787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Daube, J.R. (2000) Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve, 23, 1488&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">11003783</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson, T.D., Deitch, J.S., Blankenhorn, E.P., Erwin, K.L., Perreault, M.J., Alexander, B.K., Byers, N., Toman, I. and Alexander, G.M. (2005) Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci., 236, 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki, S. and Iwata, M. (2007) Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol., 66, 10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli, P., Belford, M.E., Lennon, N., Bacskai, B.J., Hyman, B.T., Trotti, D. and Brown, R.H., Jr. (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 43, 19&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233914</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrini, S., Sau, D., Guareschi, S., Bogush, M., Brown, R.H., Jr., Naniche, N., Kia, A., Trotti, D. and Pasinelli, P. (2010) ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum. Mol. Genet., 19, 2974&#x2013;2986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901139</ArticleId><ArticleId IdType="pubmed">20460269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J.K., Hwang, S.G., Shin, J.H., Shim, J. and Choi, E.J. (2014) CIIA prevents SOD1(G93A)-induced cytotoxicity by blocking ASK1-mediated signaling. Front. Cell. Neurosci., 8, 179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071562</ArticleId><ArticleId IdType="pubmed">25018698</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles, S., Destroismaisons, L., Peyrard, S.L., Cadot, S., Rouleau, G.A., Brown, R.H., Jr., Julien, J.P., Arbour, N. and Vande Velde, C. (2013) Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum. Mol. Genet., 22, 3947&#x2013;3959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5052069</ArticleId><ArticleId IdType="pubmed">23736301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakellariou, G.K., Pye, D., Vasilaki, A., Zibrik, L., Palomero, J., Kabayo, T., McArdle, F., Van Remmen, H., Richardson, A., Tidball, J.G. &#xa0;et al. (2011) Role of superoxide-nitric oxide interactions in the accelerated age-related loss of muscle mass in mice lacking Cu,Zn superoxide dismutase. Aging Cell, 10, 749&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531889</ArticleId><ArticleId IdType="pubmed">21443684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;gan, C., Vila, M., Rosoklija, G., Hays, A.P. and Przedborski, S. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci., 21, 6569&#x2013;6576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763092</ArticleId><ArticleId IdType="pubmed">11517246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos, I.G., Bacman, S.R., Hernandez, D., Oca-Cossio, J., Arias, L.J., Perez-Pinzon, M.A., Bradley, W.G. and Moraes, C.T. (2005) Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci., 25, 164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725219</ArticleId><ArticleId IdType="pubmed">15634778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, X., Ma, Y., Liu, Y. and Wan, Q. (2021) Measurement of mitochondrial respiration in adherent cells by Seahorse XF96 Cell Mito Stress Test. STAR Protoc., 2, 100245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797920</ArticleId><ArticleId IdType="pubmed">33458707</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne, S.E., Yang, L., DiMauro, J.P., Fuller, S.W., Licata, S.C. and Beal, M.F. (2006) Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol. Dis., 22, 599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616851</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussee, E., De Smet, P., Bogaert, E., Elens, I., Van Damme, P., Willems, P., Koopman, W., Van Den Bosch, L. and Callewaert, G. (2011) G37R SOD1 mutant alters mitochondrial complex I activity, Ca(2+) uptake and ATP production. Cell Calcium, 49, 217&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">21388680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, H., McCaffery, J.M. and Chan, D.C. (2007) Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell, 130, 548&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">17693261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Liu, Y., Dorn, G.W. and 2nd. (2011) Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ. Res., 109, 1327&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237902</ArticleId><ArticleId IdType="pubmed">22052916</ArticleId></ArticleIdList></Reference><Reference><Citation>Eschenbacher, W.H., Song, M., Chen, Y., Bhandari, P., Zhao, P., Jowdy, C.C., Engelhard, J.T., Dorn, G.W. and 2nd. (2012) Two rare human mitofusin 2 mutations alter mitochondrial dynamics and induce retinal and cardiac pathology in Drosophila. PLoS One, 7, e44296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434137</ArticleId><ArticleId IdType="pubmed">22957060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasahara, A., Cipolat, S., Chen, Y., Dorn, G.W., 2nd and Scorrano, L. (2013) Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. Science, 342, 734&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">24091702</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, M., Mihara, K., Chen, Y., Scorrano, L. and Dorn, G.W., 2nd (2015) Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metab., 21, 273&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4318753</ArticleId><ArticleId IdType="pubmed">25600785</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, M., Franco, A., Fleischer, J.A., Zhang, L. and Dorn, G.W., 2nd (2017) Abrogating mitochondrial dynamics in mouse hearts accelerates mitochondrial senescence. Cell Metab., 26, 872&#x2013;883.e875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718956</ArticleId><ArticleId IdType="pubmed">29107503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y., Carmona, S., Muhammad, A., Bell, S., Landeros, J., Vazquez, M., Ho, R., Franco, A., Lu, B., Dorn, G.W., 2nd &#xa0;et al. (2021) Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model. J. Clin. Invest., 131, e147307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810493</ArticleId><ArticleId IdType="pubmed">33463548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuchner, S., Mersiyanova, I.V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E.L., Zappia, M., Nelis, E., Patitucci, A., Senderek, J. &#xa0;et al. (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet., 36, 449&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">15064763</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeven, K., Claeys, K.G., Zuchner, S., Schroder, J.M., Weis, J., Ceuterick, C., Jordanova, A., Nelis, E., De Vriendt, E., Van Hul, M. &#xa0;et al. (2006) MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain, 129, 2093&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16714318</ArticleId></ArticleIdList></Reference><Reference><Citation>Feely, S.M., Laura, M., Siskind, C.E., Sottile, S., Davis, M., Gibbons, V.S., Reilly, M.M. and Shy, M.E. (2011) MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology, 76, 1690&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100135</ArticleId><ArticleId IdType="pubmed">21508331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombelli, F., Stojkovic, T., Dubourg, O., Echaniz-Laguna, A., Tardieu, S., Larcher, K., Amati-Bonneau, P., Latour, P., Vignal, O., Cazeneuve, C. &#xa0;et al. (2014) Charcot-Marie-Tooth disease type 2A, from typical to rare phenotypic and genotypic features. JAMA Neurol., 71, 1036&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">24957169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Dang, X., Franco, A., Zhao, H. and Dorn, G.W. (2022) Piperine derivatives enhance fusion and axonal transport of mitochondria by activating mitofusins. Chemistry, 4, 655&#x2013;668.</Citation></Reference><Reference><Citation>Franco, A., Kitsis, R.N., Fleischer, J.A., Gavathiotis, E., Kornfeld, O.S., Gong, G., Biris, N., Benz, A., Qvit, N., Donnelly, S.K. &#xa0;et al. (2016) Correcting mitochondrial fusion by manipulating mitofusin conformations. Nature, 540, 74&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315023</ArticleId><ArticleId IdType="pubmed">27775718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharioudakis, E., Agianian, B., Kumar Mv, V., Biris, N., Garner, T.P., Rabinovich-Nikitin, I., Ouchida, A.T., Margulets, V., Nordstr&#xf8;m, L.U., Riley, J.S. &#xa0;et al. (2022) Modulating mitofusins to control mitochondrial function and signaling. Nat. Commun., 13, 3775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262907</ArticleId><ArticleId IdType="pubmed">35798717</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J., Dang, X., Franco, A. and Dorn, G.W. (2022) Reciprocal regulation of mitofusin 2-mediated mitophagy and mitochondrial fusion by different PINK1 phosphorylation events. Front. Cell Dev. Biol., 10, 868465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133611</ArticleId><ArticleId IdType="pubmed">35646911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, R.Z., Jiang, S., Zhang, L. and Yu, Z.B. (2019) Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int. J. Mol. Med., 44, 3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6559295</ArticleId><ArticleId IdType="pubmed">31115493</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudet, M.J., Yang, Q., Cadau, S., Blais, M., Bellenfant, S., Gros-Louis, F. and Berthod, F. (2015) High yield extraction of pure spinal motor neurons, astrocytes and microglia from single embryo and adult mouse spinal cord. Sci. Rep., 5, 16763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649473</ArticleId><ArticleId IdType="pubmed">26577180</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>